Aurobindo reported a robust revenue growth of 25.8% YoY/ 5.4% QoQ, led by 26.9% YoY/ 4.1% growth in Formulations, while 20.3% YoY/ 12.9% QoQ growth in API (Active Pharmaceutical Ingredients). The US sales, excluding Puerto Rico sales, stood at INR 33,850 Mn, a growth of 35.7% YoY/ 7.9% QoQ. Puerto Rico sales for the quarter were 850 Mn.